Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Endocannabinoids and neurodegenerative diseases.
Relapses in patients treated with fingolimod after previous exposure to natalizumab.
Four Square Step Test in ambulant persons with multiple sclerosis: validity, reliability, and responsiveness.
Extensive loss of connexins in Baló's disease: evidence for an auto-antibody-independent astrocytopathy via impaired astrocyte-oligodendrocyte/myelin interaction.
FDA approves injectable drug to treat opioid-dependent patients
Association of human endogenous retroviruses with multiple sclerosis and possible interactions with herpes viruses.
Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.
The role of mitochondria in axonal degeneration and tissue repair in MS.
Modeling the variability in brain morphology and lesion distribution in multiple sclerosis by deep learning.
Demyelinating Diseases: Myeloperoxidase as an Imaging Biomarker and Therapeutic Target.
Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: Relationship to oxidative stress.
Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis.
Isolated trigeminal nerve palsy with motor involvement as a presenting manifestation of multiple sclerosis in an equatorial region - a case report.
Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab.
Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning.
Tapered withdrawal of phenytoin removes protective effect in EAE without inflammatory rebound and mortality.
European ancestry predominates in neuromyelitis optica and multiple sclerosis patients from Brazil.
Catheter venography and endovascular treatment of chronic cerebrospinal venous insufficiency.
Dimethyl fumarate (Tecfidera) for multiple sclerosis.
Contribution of imaging to the diagnosis of optic neuropathies.
Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and mice.
The Arabic version of the Mayo-Portland Adaptability Inventory 4: a validation study.
[2012: Update on diagnosis and treatment of multiple sclerosis].
Multiple cutaneous necrotic lesions associated with Interferon beta-1b injection for multiple sclerosis treatment: A case report and literature review.
Biomarkers in multiple sclerosis.
Pages
« first
‹ previous
…
140
141
142
143
144
145
146
147
148
…
next ›
last »